Atlanta, GA– GeoVax Labs, Inc. (BULLETIN BOARD: GOVX) , an Atlanta- based HIV/AIDS vaccine development company, has entered into a $10 million common stock purchase agreement with Fusion Capital Fund II of Chicago.

The company may sell up to $10 million of its common stock to Fusion Capital from time to time over a 25-month period after the Securities and Exchange Commission has declared effective a registration statement related to the transaction. GeoVax will use the proceeds to further its developmental HIV/AIDS vaccine, expected to enter Phase 2 human clinical trials later this year.

Dr. Robert T. McNally, GeoVax president and CEO said, “This agreement will help us continue to move forward with our AIDS vaccine development efforts. Combined with the five- year, $15 million federal grant GeoVax was awarded last year and the direct support we expect to receive through the HIV Vaccine Trials Network conducting our upcoming Phase 2 clinical trial, we believe we are well- positioned to achieve several important milestones in the development of our vaccine.

“This agreement also provides flexibility for us to choose the times at which we accept capital, and to consider other alternative financing sources should the opportunity arise.”

http://www.techjournalsouth.com/news/article.html?item_id=5337